Literature DB >> 8653702

Interleukin 2 (IL-2) receptor expression and sensitivity to diphteria fusion toxin DAB389IL-2 in cultured hematopoietic cells.

G G Re1, C Waters, L Poisson, M C Willingham, K Sugamura, A E Frankel.   

Abstract

The high-affinity interleukin 2 (IL-2) receptor is a heterotrimer consisting of alpha, beta, and gamma subunits. We examined the concentration of subunit mRNA for each of the three protein subunits on human hematopoietic cell lines, human peripheral blood mononuclear cells, and murine fibroblasts transfected with cDNAs encoding the human IL-2 receptor subunits. In most cultured hematopoietic cells, there was abundant gamma subunit message. In contrast, there was variable expression of both alpha and beta subunit message. Sensitivity of cells to the diphtheria fusion toxin DAB389IL-2 was not related to expression of any single IL-2 receptor subunit mRNA. Rather, the greatest sensitivity was observed for cells possessing all three subunit mRNAs. Cells displaying beta and gamma subunit mRNA showed a reduced but significant sensitivity to the fusion toxin. In contrast, cells with alpha and gamma subunit mRNA, but missing the beta subunit mRNA, were insensitive to DAB389IL-2. The data correlate with the requirement for an intermediate or a high-affinity receptor for cell intoxication. A critical concentration of the beta subunit may be required for toxin internalization and killing.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8653702

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Second-generation IL-2 receptor-targeted diphtheria fusion toxin exhibits antitumor activity and synergy with anti-PD-1 in melanoma.

Authors:  Laurene S Cheung; Juan Fu; Pankaj Kumar; Amit Kumar; Michael E Urbanowski; Elizabeth A Ihms; Sadiya Parveen; C Korin Bullen; Garrett J Patrick; Robert Harrison; John R Murphy; Drew M Pardoll; William R Bishai
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-04       Impact factor: 11.205

2.  Resimmune, an anti-CD3ε recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma.

Authors:  Arthur E Frankel; Jung H Woo; Chul Ahn; Francine M Foss; Madeleine Duvic; Paul H Neville; David M Neville
Journal:  Haematologica       Date:  2015-03-20       Impact factor: 9.941

3.  IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity.

Authors:  Mary T Litzinger; Romaine Fernando; Tyler J Curiel; Douglas W Grosenbach; Jeffrey Schlom; Claudia Palena
Journal:  Blood       Date:  2007-07-06       Impact factor: 22.113

4.  Differential effects of denileukin diftitox IL-2 immunotoxin on NK and regulatory T cells in nonhuman primates.

Authors:  Yohei Yamada; Akihiro Aoyama; Georges Tocco; Svjetlan Boskovic; Ognjenka Nadazdin; Alessandro Alessandrini; Joren C Madsen; A Benedict Cosimi; Gilles Benichou; Tatsuo Kawai
Journal:  J Immunol       Date:  2012-05-14       Impact factor: 5.422

5.  Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and Sézary syndrome.

Authors:  H Miles Prince; Ann G Martin; Elise A Olsen; David P Fivenson; Madeleine Duvic
Journal:  Leuk Lymphoma       Date:  2012-09-14

Review 6.  Toxin-based therapeutic approaches.

Authors:  Assaf Shapira; Itai Benhar
Journal:  Toxins (Basel)       Date:  2010-10-28       Impact factor: 4.546

Review 7.  Recent advances with Treg depleting fusion protein toxins for cancer immunotherapy.

Authors:  Pankaj Kumar; Amit Kumar; Sadiya Parveen; John R Murphy; William Bishai
Journal:  Immunotherapy       Date:  2019-07-30       Impact factor: 4.040

8.  Denileukin diftitox for the treatment of cutaneous T-cell lymphoma.

Authors:  David Kaminetzky; Kenneth B Hymes
Journal:  Biologics       Date:  2008-12

Review 9.  Targeted Approaches to T-Cell Lymphoma.

Authors:  Sean Harrop; Chathuri Abeyakoon; Carrie Van Der Weyden; H Miles Prince
Journal:  J Pers Med       Date:  2021-05-27

10.  Interleukin-1 alpha increases the preferential cytotoxicity of an interleukin-2-diphtheria toxin fusion protein against neoplastic lymphocytes from patients with the Sezary syndrome compared to normal lymphocytes.

Authors:  D Salard; T M Kuzel; E Samuelson; S Rosen; O Bakouche
Journal:  J Clin Immunol       Date:  1998-05       Impact factor: 8.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.